Mechanistic and functional characterization of NETs/IL-17 as a therapeutic target in EMT and brain metastasis of lung adenocarcinoma - Scorecard - MDSpire
Advertisement
Mechanistic and functional characterization of NETs/IL-17 as a therapeutic target in EMT and brain metastasis of lung adenocarcinoma
Clinical Scorecard: Exploring the Role of IL-17A and Neutrophil Extracellular Traps in Epithelial-Mesenchymal Transition and Brain Metastasis in Lung Adenocarcinoma
At a Glance
Category
Detail
Condition
Key Mechanisms
IL-17A-induced NET formation, EMT, and brain metastasis, with emphasis on H2BC4 involvement.
Target Population
Care Setting
Key Highlights
IL-17A stimulates NET formation in neutrophils.
NETs enhance tumor metastasis to the brain.
Acetylation of H2BC4 is associated with IL-17A and NETs.
NETs play a role in epithelial-mesenchymal transition (EMT).
Patients with brain metastases from LUAD have a poor prognosis.
H2BC4 is identified as a key gene in the NETs pathway.
Guideline-Based Recommendations
Diagnosis
Management
Consider targeted therapies in addition to surgery or radiotherapy for palliative care.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with Lung Adenocarcinoma at risk for brain metastasis.
Potential therapeutic targets include the IL-17A/NETs/H2BC4 pathway.
Clinical Best Practices
Consider the role of NETs in the metastatic process of LUAD.
Investigate IL-17A levels in patients with LUAD for potential therapeutic insights.
Utilize p300 inhibitors as a potential strategy in managing LUAD with brain metastasis, supported by recent studies.
